



WEDNESDAY 20th APRIL 2016 COMMENCING 09:30 AM

AT THE [PARK INN HOTEL CARDIFF NORTH](#), CIRCLE WAY EAST
LLANEDYRN, CARDIFF, CF23 9XF

AGENDA

- | | |
|--------------------------------|--------------|
| | Enclosure |
| 1. Welcome and introduction | |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0416 |

To protect commercial confidentiality the following appraisal will be held in private

- | | |
|--|----------------------------|
| 5. Appraisal 1: Full Submission (WPAS)
Eribulin mesilate (Halaven[®]) for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments | 2/AWMSG/0416
Appendices |
|--|----------------------------|

The meeting will now open to the public (approximately 10.30am)

- | | |
|---|----------------------------|
| 6. Chairman's report (verbal update) | |
| 7. Appraisal 2: Limited Submission
Ursodeoxycholic acid (Ursofalk[®]) for the treatment of hepatobiliary disorders associated with cystic fibrosis in children aged 1 month to 18 years | 3/AWMSG/0416
Appendices |

Date of next meeting: 18th May 2016 in Cardiff